J. Kellogg Parsons, MD, MHS, FACS, discusses the role of the National Comprehensive Cancer Network (NCCN) Prostate Cancer Early Detection guidelines in the PSA screening debate. He then provides commentary on the three algorithms included in the guidelines.
Read More
Alan H. Bryce, MD, explains the concept of synthetic lethality in the context of BRCA-deficient tumors, as well as resistance to poly (ADP-ribose) polymerase (PARP) inhibition. He also discusses the under-utilization of inherited cancer risk syndromes in prostate cancer practice, research, and guidelines, as well as new pathways for therapeutic targeting
Read More
J. Kellogg Parsons, MD, MHS, FACS, reviews general principles of patient safety as applied to urologic practice. He provides practical instructions about handling urologic complications, specifically rhabdomyolysis, venous thromboembolism (VTE), air embolism, laparoscopic bowel injury, and prostate biopsy infections.
Read More
J. Kellogg Parsons, MD, MHS, FACS, reviews the 2018 American Urological Association (AUA) Guidelines for benign prostatic hyper-plasia (BPH). He emphasizes the topics excluded from the guidelines, as well as statements on preoperative evaluation, surgical therapies, and medically-complicated patients.
Read More
Sigrid V. Carlsson, MD, PhD, MPH, reviews the history of PSA screening, from its discovery to the controversy related to United States Preventive Services Task Force (USPSTF) gradings during the current era. She also assesses the harms and benefits of PSA screening and responsible application of the PSA test.
Read More